The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...

"FDA grants ODD to Tempest’s hepatocellular carcinoma treatment" was originally created and published by Pharmaceutical ...

Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

The following is a summary of “Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, ...

The FDA granted orphan drug designation to amezalpat in hepatocellular carcinoma based on phase 1b/2 data showing efficacy ...

Tevimbra is under clinical development by BeiGene and currently in Phase III for Hepatocellular Carcinoma. According to GlobalData, Phase III drugs for Hepatocellular Carcinoma have a 47% phase ...

Camrelizumab is under clinical development by Elevar Therapeutics and currently in Pre-Registration for Hepatocellular Carcinoma.

The following is a summary of “Development models to predict complication and prognosis following liver resection for ...

Announcing a new publication for Acta Materia Medica journal. Fatty acid (FA) reprogramming has a significant role in liver cancer. However, the contribution of FA metabolism reprogramming to the ...

Advances in therapy are improving outcomes for patients, but the incidence and mortality rates for hepatocellular carcinoma ...

However, the contribution of FA metabolism reprogramming to the heterogeneity of hepatocellular carcinoma (HCC) has not been established. This article describes how bioinformatics analysis using ...

Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in ...